SCHEMBL9801925

SCHEMBL9801925

CO[PH](O)(O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5077203 0.74
SCHEMBL13854612 0.74
SCHEMBL5071885 0.74
SCHEMBL2570805 0.74
SCHEMBL3045535 0.70
SCHEMBL9577551 0.70
SCHEMBL26501754 0.70
SCHEMBL23133186 0.67
SCHEMBL16473251 0.67
SCHEMBL11427104 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023225320-A1 EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF NOVARTIS AG (CH) 2023-11-23 WO disclosed
WO-2023225336-A1 MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF NOVARTIS AG (CH) 2023-11-23 WO disclosed
EP-3743430-B1 AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2023-08-02 EP disclosed
WO-2022115477-A1 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF NOVARTIS AG (CH) 2022-06-02 WO disclosed
WO-2022115451-A1 MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE NOVARTIS AG (CH) 2022-06-02 WO disclosed
WO-2021100029-A2 PRODRUGS OF FULVESTRANT KASHIV BIOSCIENCES, LLC (US) 2021-05-27 WO disclosed
WO-2020236825-A2 MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE NOVARTIS AG (CH) 2020-11-26 WO disclosed
WO-2020236841-A2 ANTIBODY DRUG CONJUGATES HAVING LINKERS COMPRISING HYDROPHILIC GROUPS NOVARTIS AG (CH) 2020-11-26 WO disclosed
WO-2020236817-A2 MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE NOVARTIS AG (CH) 2020-11-26 WO disclosed
WO-2019184919-A1 ADAMANTANE-CONTAINING COMPOUND AND USE THEREOF IN TREATING CANCER 成都海创药业有限公司 2019-10-03 WO disclosed
US-20150307430-A1 HYDROFORMYLATION PROCESS UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY LLC 2015-10-29 US disclosed
EP-2928855-A1 HYDROFORMYLATION PROCESS Dow Technology Investments LLC (US) 2015-10-14 EP disclosed
US-20140342363-A1 Sample Preparation INTELLIGENT BIO-SYSTEMS, INC. (US) 2014-11-20 US disclosed
US-8883999-B2 Methods and solutions for inhibiting undesired cleaving of labels Intelligent Bio Systems, Inc. (US) 2014-11-11 US disclosed
WO-2014088816-A1 HYDROFORMYLATION PROCESS DOW TECHNOLOGY INVESTMENTS LLC (US) 2014-06-12 WO disclosed
US-8177994-B2 Electrolytic solution for aluminum electrolytic capacitors, and aluminum electrolytic capacitor using the same SANYO CHEMICAL INDUSTRIES, LTD. (JP) 2012-05-15 US disclosed
US-7943751-B2 Ladder copolymers NEW YORK UNIVERSITY (US) 2011-05-17 US disclosed
US-20090256105-A1 ELECTROLYTIC SOLUTION FOR ALUMINUM ELECTROLYTIC CAPACITORS, AND ALUMINUM ELECTROLYTIC CAPACITOR USING THE SAME SANYO CHEMICAL INDUSTRIES, LTD. (JP) 2009-10-15 US disclosed
EP-0115613-B1 DNA SEQUENCES, THEIR PREPARATION, PLASMIDS CONTAINING THESE SEQUENCES AND THEIR USE IN THE SYNTHESIS OF EUKARYOTIC GENE PRODUCTS IN PROKARYOTES BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) 1991-03-27 EP disclosed
US-4469863-A ANTITUMOR AGENTS, VIRICIDES GENTA INCORPORATED 1984-09-04 US disclosed